Table 1.

RCA^aanalysis of azole–resistant C. albicans isolates with known ERG11 mutations^b.

			MIC (μg/ml)
Patient no.	Isolate no.	Body site of isolation	FLUa	VORa	Previously-characterized amino acid substitution(s)	Erg11p substitution(s) by RCA
1	C438	Oropharynx	128	2	Y257H, G464S	Y257H, G464S
	C440	Oropharynx	>256	>16	A61V, Y257H, G307S, G464S	A61V, Y257H, G307S, G464S
2	C470	Oropharynx	32	0.25	S405F	S405F
3	C480	Oropharynx	128	8	G464S, K128T, R467I	G464S, K128T, R467I
4	C507	Oropharynx	64	8	G464S, H283R, Y132H	G464S, H283R, Y132H
5	C527	Oropharynx	256	4	G450E, Y132H	G450E, Y132H
6	C577	Oropharynx	128	0.5	G464S	G464S
7	C594	Oropharynx	128	16	S405F, Y132H	S405F, Y132H

^a Abbreviations: RCA, rolling circle amplification; FLU, fluconazole; VOR, voriconazole.

^b Chau et al. [15].